

## DAFTAR PUSTAKA

- Abdulfatai U, Uzairu A, Uba S. 2016. Quantitative structure-activity relationship and molecular docking studies of a series of quinazolinonyl analogues as inhibitors of gammaamino butyric acid aminotransferase. *J. Adv. Res.* 8.doi:10.1016/j.jare.2016.10.004
- Antona, CR, Bort, R, Jover, R, Tindberg, N, Sundberg, MI, Lechon, MJG, Castell, JV. 2003. Transcription Regulation of CYP3A4 Basal Expression by CCAAT Enhancer-Binding Protein  $\alpha$  and Hepatocyte Nuclear Factor-3. *Mol. Pharm.* 63(5): 1180-1189.
- Baek, S.C., Choi, B., Nam, S.-J., & Kim, H., 2018. Inhibition of monoamine oxidase A and B by demethoxycurcumin and bisdemethoxycurcumin. *Journal of Applied Biological Chemistry, Korean Society for Applied Biological Chemistry*. <https://doi.org/10.3839/jabc.2018.027>
- Chainani-Wu, N., Madden, E., & Lozada-Nur, F. (2003). High-dose curcuminoids are efficacious in the reduction of symptoms and signs of oral lichen planus. *Journal of the American Academy of Dermatology*, 49(5), 832-841.
- Claeson, P., Panthong, A., Sripanidkulchai, B., & *et al.* (1994). Anti-inflammatory activity of extracts from plants used in traditional medicine in Thailand. *Journal of Ethnopharmacology*, 28(2), 205-211.
- Cole, J., Nissink, J., Taylor, R. 2005 Jan 1. Protein-ligand docking and virtual screening with GOLD. *Virtual Screen. Drug Discov.*:379–415.
- Da'i, M., Wulandari, R., Utami, M., 2001. Uji Aktivitas Penangkapan Radikal DPPH Analog Kurkumin Siklik dan N-heterosiklik monoketon, *Pharmacon*, 12(1), 19–25.
- Dei Cas, M., & Ghidoni, R. (2019). Dietary Curcumin: Correlation between Bioavailability and Health Potential. *Nutrients*, 11(9), 2147. MDPI AG. <http://dx.doi.org/10.3390/nu11092147>
- Dar, A.M., dan Mir, S., 2017. Molecular Docking: approaches, Types, Applications, and Basic challenges, *Journal of Analytical & Bioanalytical Techniques*, 08:.
- DiMasi, J. A., Grabowski, H. G., & Hansen, R. W. 2016. Innovation in the pharmaceutical industry: New estimates of R&D costs. *Journal of health economics*, 47, 20–33. <https://doi.org/10.1016/j.jhealeco.2016.01.012>
- Foti, R. S., Rock, D. A., Han, X., Flowers, R. A., Wienkers, L. C., & Wahlstrom, J. L. (2012). Ligand-based design of a potent and selective inhibitor of cytochrome P450 2C19. *Journal of medicinal chemistry*, 55(3), 1205–1214. <https://doi.org/10.1021/jm201346g>
- Goldstein, J.A., J., Br. (2001). *Clinical Pharmacology*. 52. 349-355.
- Guengerich, FP. 2008. Cytochrome P450 and Chemical Toxicology. *Chem. Res. Toxicol.* 21.
- Higashi, M.K., Veenstra DL, Kondo LM, *et al.* 2002. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. *JAMA*. 287(13):1690-1698. doi: 10.1001/jama.287.13.1690

- Hulot, J.S., Bura, A., Villard, E., *et al.* Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. *Blood*. 2006;108(7):2244-2247. doi: 10.1182/blood-2006-04-013052
- Ireson, C. R., Jones, D. J., Orr, S., Coughtrie, M. W., Boocock, D. J., Williams, M. L., & Gescher, A. J. 2002. Metabolism of the cancer chemopreventive agent curcumin in human and rat intestine. *Cancer Epidemiology Biomarkers & Prevention*, 11(1), 105-111.
- Iyanagi, Takashi. 2007. Molecular mechanism of phase I and phase II drug-metabolizing enzymes: implications for detoxification. <https://pubmed.ncbi.nlm.nih.gov/17482904/>
- Kitchen, D.B., Decornez, H., Furr, John R., & Bajorath, J., 2004. Docking and scoring in Virtual Screening for Drug Discovery: Methods and Applications, *Nat. Rev.* 3, 935–949.
- Kunnumakkara, A. B., Bordoloi, D., Padmavathi, G., Monisha, J., Roy, N. K., Prasad, S., & Aggarwal, B. B. 2017. Curcumin, the golden nutraceutical: multitargeting for multiple chronic diseases. *British journal of pharmacology*, 174(11), 1325–1348. <https://doi.org/10.1111/bph.13621>
- Kuttan, R., Sudheeran, P. C., & Josph, C. D. 1985. Turmeric and curcumin as topical agents in cancer therapy. *Tumori Journal*, 71(5), 287-292.
- Leach, A. R., & Gillet, V. J. (2007). *An introduction to chemoinformatics*. Springer Science & Business Media.
- Liang, G., Yuan, W., Xi, T., & Zhou, X. (2009). Synthesis and biological activity evaluation of curcumin analogues with the influence of different carbon-chain spacers. *Medicinal Chemistry Research*, 18(6), 337-347.
- Lutomskey, J., Stockenhuber, R., Bramm, G., *et al.* (1974). Pharmacological investigation of turmeric constituents. *Planta Medica*, 25(3), 277-286.
- Mandlik, V., Rath, B., & Madamwar, D. 2016. QSAR modeling for design of novel antimicrobial agents. In *QSAR and molecular modeling in rational design of bioactive molecules* (pp. 287-322). Elsevier.
- Marbun, P., Hakim, A., Ujiantari, N., Sudarmanto, B., Nugroho, A. (2023). *In silico* Pharmacokinetics Study of 2,5-Dibenzylidenecyclopentanone Analogs as Mono-Ketone Versions of Curcumin. *BIO Web of Conferences*. 75. 10.1051/bioconf/20237504002.
- Mazumder, A., Raghavan, K., Weinstein, J., & Kohn, K. W. 1997. P-Glycoprotein-mediated drug efflux and radiation resistance in human breast cancer cells. *International Journal of Radiation OncologyBiologyPhysics*, 37(1), 207-212.
- Meiyanto, E., Hermawan, A., Anindyajati, A., *et al.* (2014). The molecular mechanism of anticancer effects of the curcumin analog GO-Y030. *Current Pharmacology Reports*, 1(2), 61-70.
- Meng, X.Y., Zhang, H.X., Mezei, M., & Cui, M. (2011). Molecular docking: A powerful approach for structure-based drug discovery, *Curr.Comp-Aided Drug Des.* 7(2),146–157.

- Molecular Operating Environment (MOE). (2015). Chemical Computing Group ULC. 910-1010 Sherbrooke St. W., Montreal, QC H3A 2R7, Canada. 2024.
- Oetari, R.A., Sardjiman, Yuwono, T., dan Hakim, L., 2001, Upaya Peningkatan Absorpsi Senyawa Baru Antiinflamasi PGV-0, Laporan Penelitian Hibah Bersaing IX/1 Perguruan Tinggi, Lembaga Penelitian Universitas Gadjah Mada, 17
- Paxton, J., 2012, Topics on Drug Metabolism. InTech. doi:10.5772/1180.
- Priyadarsini, K.I., 2014. The chemistry of curcumin: from extraction to therapeutic agent, *Molecules* (Basel, Switzerland), 19(12), 20091– 20012. <https://doi.org/10.3390/molecules191220091>.
- Ramirez, D., Caballero, J. 2018. Is It Reliable to Take the Molecular Docking Top Scoring Position as the Best Solution without Considering Available Structural Data? *Molecules*. 23(5):1038.doi:10.3390/molecules23051038
- Ramprasad, N., & Sirsi, M. (1957). Cholagogue and choleretic activity of curcumin and related compounds. *Indian Journal of Medical Research*, 45(3), 299-306.
- Rester, U., 2008. From virtual to reality - Virtual screening in lead discovery and lead optimization: a medicinal chemistry perspective. *Current Opinion in Drug Discovery & Development*, 11: 559 – 568.
- Rettie AE, Jones JP. Clinical and toxicological relevance of CYP2C9: drug-drug interactions and pharmacogenetics. *Annu Rev Pharmacol Toxicol*. 2005;45:477-494. doi: 10.1146/annurev.pharmtox.45.120403.095821
- Richert, L. (2015). Canadian Society of Pharmacology and Therapeutics. In S. Boslaugh (Ed.), *Sage Encyclopaedia of Pharmacology and Society* (pp. 306-308) <https://doi.org/10.4135/9781483349985.n90>
- Sardjiman, S., MS Reksohadiprodjo., Hakim, L., H Van der Goot., H Timmermen. 1997. 1,5- Diphenyl-1,4-pentadiene-3-ones and cyclic analogues as antioxidative agents. Synthesis and structure-activity relationship. *Eur J Med Chem*. Paris.
- Sardjiman. (2000). Synthesis of Some New Series of Curcumin Analogues, Antioxidative, Antiinflammatory, Antibacterial Activity, and Qualitative Structure Activity Relationship. Disertasi. UGM. Yogyakarta.
- Scott SA. Personalizing medicine with clinical pharmacogenetics. *Genet Med*. 2011;13(12):987-995. doi: 10.1097/GIM.0b013e318238bba2
- Stuppaeck CH, Pycha R, Miller C, *et al*. Poor CYP2C19 metabolizer status may be associated with adverse events after treatment with escitalopram in psychiatric patients. *Int Clin Psychopharmacol*. 2007;22(4):241-245. doi: 10.1097/YIC.0b013e3281339434
- Shankar, T. N. B., & Murthy, V. S. (1979). Antibacterial activity of curcumin. *Indian Journal of Experimental Biology*, 17(8), 799-800.
- Sharifi-Rad, J., Rayess, Y. E., Rizk, A. A., Sadaka, C., Zgheib, R., Zam, W., Sestito, S., Rapposelli, S., Neffe-Skocińska, K., Zielińska, D., Salehi, B., Setzer, W. N., Dosoky, N. S., Taheri, Y., El Beyrouthy, M., Martorell, M., Ostrander, E. A., Suleria, H. A. R., Cho, W. C., Maroyi, A., ... Martins, N. (2020). Turmeric and

- Its Major Compound Curcumin on Health: Bioactive Effects and Safety Profiles for Food, Pharmaceutical, Biotechnological and Medicinal Applications. *Frontiers in pharmacology*, 11, 01021. <https://doi.org/10.3389/fphar.2020.01021>.
- Sharma, R. A., McLelland, H. R., & Hill, K. A. (1972). Antioxidant activity of curcumin and related compounds. *Biochemical Pharmacology*, 21(7), 1037-1048.
- Srimal, R. C., & Dhawan, B. N. (1973). Pharmacology of diferuloyl methane (curcumin), a non-steroidal anti-inflammatory agent. *Journal of Pharmacy and Pharmacology*, 25(6), 447-452.
- Teo, Y. L., Ho, H. K., & Chan, A. (2015). Metabolism-related pharmacokinetic drug-drug interactions with tyrosine kinase inhibitors: current understanding, challenges and recommendations. *British journal of clinical pharmacology*, 79(2), 241–253. <https://doi.org/10.1111/bcp.12496> diakses pada 19 mei 2023.
- Tropsha, A. (2010). Best practices for QSAR model development, validation, and exploitation. *Molecular informatics*, 29(6-7), 476-488.
- Wahlstrom, B., & Blennow, G. (1978). A study on the fate of curcumin in the rat. *Acta pharmacologica et toxicologica*, 43(2), 86-92. <https://doi.org/10.1111/j.1600-0773.1978.tb02240.x>
- Wedlund, P.J. (2000) *Pharmacology*, 61, 174-183.